MM-111

DRUG2 trials

Sponsors

Merrimack Pharmaceuticals

Conditions

Esophagus CancerGastroesophageal Junction CancerHER-2 Gene AmplificationHer2 Amplified Solid TumorsMetastatic Breast CancerStomach Cancer

Phase 1

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

CompletedNCT00911898

Merrimack PharmaceuticalsHer2 Amplified Solid Tumors, Metastatic Breast Cancer

Start: 2009-06-30End: 2012-03-31Updated: 2015-01-13

Phase 2

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

TerminatedNCT01774851

Merrimack PharmaceuticalsEsophagus Cancer, Gastroesophageal Junction Cancer, HER-2 Gene Amplification +1

Start: 2013-01-31End: 2015-12-31Updated: 2017-06-22

Related Papers

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).

Journal of Clinical Oncology2016-05-2022 citations

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.

Journal of Clinical Oncology2014-05-207 citations